Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards
- PMID: 19067650
- DOI: 10.1021/tx8003328
Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards
Abstract
The recent guidance on "Safety Testing of Drug Metabolites" issued by the U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER) has highlighted the importance of identifying and characterizing drug metabolites as early as possible in drug discovery and development. Furthermore, upon identifying significant circulating metabolites in human plasma, it has become important to demonstrate that these metabolites are present at an equal or greater exposure level (area under the curve, AUC) in any one of the preclinical species used in safety testing. Frequently, synthetic standards of metabolites are not available, and hence, obtaining their AUC values can be a challenge. In this report, we demonstrate how combinations of nuclear magnetic resonance (NMR) spectroscopy, liquid chromatography/ultraviolet/mass spectrometry (LC/UV/MS), and plasma pooling methods were used to obtain reliable AUC values of metabolites present in the plasma of preclinical species from short-term safety studies. Plasma pooling methods were compared to the traditional approaches of obtaining quantitative information on the levels of circulating metabolites in preclinical species. The exposure values obtained via sample pooling were comparable to those obtained by traditional methods of analyzing samples individually. In the absence of synthetic chemical standards, calculations of AUC values of metabolites, using either sample pooling or traditional approaches, were achieved through the use of UV detectors. In cases where the UV properties of metabolites were significantly different from their parent compounds, NMR was used as a quantitative tool to obtain exposure values. NMR was found to be useful in quantitating biologically produced metabolites, which could subsequently be used as reference compounds for further quantitative studies. The limitations of UV detectors to obtain exposure estimates are discussed. A practical solution is presented that will enable us to obtain a quantitative assessment of metabolite exposure in humans and coverage in toxicology species, hence, circumventing the use of radiolabeled compounds or authentic chemically synthesized standards of metabolites.
Similar articles
-
Nuclear magnetic resonance spectroscopy as a quantitative tool to determine the concentrations of biologically produced metabolites: implications in metabolites in safety testing.Chem Res Toxicol. 2009 Feb;22(2):299-310. doi: 10.1021/tx800251p. Chem Res Toxicol. 2009. PMID: 18980340
-
Determination of exposure multiples of human metabolites for MIST assessment in preclinical safety species without using reference standards or radiolabeled compounds.Chem Res Toxicol. 2010 Dec 20;23(12):1871-3. doi: 10.1021/tx100363k. Chem Res Toxicol. 2010. PMID: 21121646
-
Alternate strategies to obtain mass balance without the use of radiolabeled compounds: application of quantitative fluorine (19F) nuclear magnetic resonance (NMR) spectroscopy in metabolism studies.Chem Res Toxicol. 2012 Mar 19;25(3):572-83. doi: 10.1021/tx2005629. Epub 2012 Feb 10. Chem Res Toxicol. 2012. PMID: 22292524
-
Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development.Chem Res Toxicol. 2009 Feb;22(2):280-93. doi: 10.1021/tx800432c. Chem Res Toxicol. 2009. PMID: 19183054 Review.
-
A holistic strategy for characterizing the safety of metabolites through drug discovery and development.Chem Res Toxicol. 2009 Oct;22(10):1653-62. doi: 10.1021/tx900213j. Chem Res Toxicol. 2009. PMID: 19715349 Review.
Cited by
-
Meeting report: metabolites in safety testing (MIST) symposium-safety assessment of human metabolites: what's REALLY necessary to ascertain exposure coverage in safety tests?AAPS J. 2013 Oct;15(4):970-3. doi: 10.1208/s12248-013-9502-6. Epub 2013 Jul 3. AAPS J. 2013. PMID: 23821354 Free PMC article.
-
Human absorption, distribution, metabolism and excretion properties of drug molecules: a plethora of approaches.Br J Clin Pharmacol. 2014 Dec;78(6):1185-200. doi: 10.1111/bcp.12468. Br J Clin Pharmacol. 2014. PMID: 25041729 Free PMC article.
-
Detection of nanolevel drug metabolites in an organotypic culture of primary human hepatocytes and porcine hepatocytes with special reference to a two-compartment model.Int J Nanomedicine. 2012;7:5859-72. doi: 10.2147/IJN.S29651. Epub 2012 Nov 27. Int J Nanomedicine. 2012. PMID: 23226017 Free PMC article.
-
Addressing the challenges of low clearance in drug research.AAPS J. 2015 Mar;17(2):352-7. doi: 10.1208/s12248-014-9691-7. Epub 2015 Jan 8. AAPS J. 2015. PMID: 25567366 Free PMC article. Review.
-
Significance of Competing Metabolic Pathways for 5F-APINACA Based on Quantitative Kinetics.Molecules. 2020 Oct 20;25(20):4820. doi: 10.3390/molecules25204820. Molecules. 2020. PMID: 33092129 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical